- Home
- HTFL vs PRCT Comparison
HTFL vs PRCT Comparison
Compare HTFL & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HTFL | PRCT |
|---|---|---|
| Founded | 2007 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.0B |
| IPO Year | 2025 | 2021 |
Fundamental Metrics
Financial Performance| Metric | HTFL | PRCT |
|---|---|---|
| Price | $27.51 | $35.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $39.50 | ★ $56.57 |
| AVG Volume (30 Days) | 666.3K | ★ 1.6M |
| Earning Date | 11-12-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $161,881,000.00 | ★ $299,907,000.00 |
| Revenue This Year | $40.42 | $48.34 |
| Revenue Next Year | $22.27 | $29.35 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 85.70 | 50.07 |
| 52 Week Low | $25.75 | $27.80 |
| 52 Week High | $41.22 | $98.38 |
Technical Indicators
Market Signals| Indicator | HTFL | PRCT |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 63.94 |
| Support Level | N/A | $29.04 |
| Resistance Level | N/A | $32.93 |
| Average True Range (ATR) | 0.00 | 1.76 |
| MACD | 0.00 | 0.84 |
| Stochastic Oscillator | 0.00 | 81.52 |
Price Performance
Historical ComparisonAbout HTFL Heartflow Inc. Common Stock
HeartFlow Inc is a commercial-stage medical technology company that has pioneered the use of software and AI to deliver a non-invasive solution for diagnosing and managing coronary artery disease CAD. The company operates and manages its business as one reportable and operating segment, which is the business of non-invasive coronary artery disease detection solutions. Geographically, it operates in United States, United Kingdom, Japan, and Rest of Europe, of which it derives maximum revenue from United States.
About PRCT PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.